Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AxoGen Inc AXGN

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.


NDAQ:AXGN - Post by User

Bullboard Posts
Next >>
Post by AviseAnalyticson Jan 24, 2024 7:38am
79 Views
Post# 35842408

AXOGEN: REPAIRING LIVES OF PATIENTS WITH PERIPHERAL NERVE IN

AXOGEN: REPAIRING LIVES OF PATIENTS WITH PERIPHERAL NERVE IN
$AXGN

Excited to share an article about  Axogen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries.

For Q3 FY23, the Company's revenue was $41.3 million, an increase of approximately 12% over Q3 FY22. For FY23, revenue guidance is in the range of $154 million to $159 million, which represents annual growth of 11% - 15% and a gross margin of 80%. 

The Company operates in the nerve industry, with a market opportunity of more than $2.7 billion. Since 2016, it has grown at a CAGR of 22%. It seems that Axogen will continue on this upward trajectory, making it an interesting watch.

Read on to know more:
https://www.aviseanalytics.com/axogen-repairing-lives-of-patients-with-peripheral-nerve-injuries/
 
 
 

Bullboard Posts
Next >>